Summary: Financial Times investigates the momentum surrounding clinical research into treating medical conditions with psychedelics including MDMA, LSD, psilocybin, and ayahuasca. The article details the origins of psychedelic research, analyzes how the criminalization of psychedelics hinders research that could provide new treatments, and highlights the importance of continuing psychedelic research through interviews with MAPS Founder Rick Doblin, Ph.D., MDMA-assisted psychotherapy study participants Rachel Hope and Tony Macie, and others. “I have never been able to think so clearly or had so much peace in my life,” explains Macie. “I’m not saying it’s for everyone. But our government wants to send us to war where they accept we could die, then when we get home they don’t want us to get treatment. It’s the least they owe us.”